marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-13-2024
Cidara Therapeutics Balance Sheet 2011-2024 | CDTX
Annual Balance Sheet Cidara Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-57.2 M | -28 M | -38.5 M | -64.6 M | -50.9 M | -56.3 M | -62.6 M | -22.8 M | 1.3 M | - | - | ||
Long Term Debt |
575 K | - | 1.32 M | - | - | - | 7.21 M | 9.79 M | - | - | 1.48 M | - | - |
Long Term Debt Current |
1.08 M | 1.21 M | 1.15 M | 939 K | 818 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 942 K | 81 K | 7.21 M | 9.87 M | 88 K | 34 K | 1.48 M | - | - |
Total Current Liabilities |
67.4 M | 41.4 M | 34 M | 38.6 M | 30.2 M | 19.9 M | 12.1 M | 8.91 M | 5.97 M | - | - | - | - |
Total Liabilities |
75.2 M | 61.9 M | 53.8 M | 49.7 M | 31.1 M | 20 M | 19.3 M | 18.8 M | 6.06 M | 3.25 M | 1.6 M | - | - |
Deferred Revenue |
- | - | - | - | 9.8 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-441 M | -418 M | -377 M | -335 M | -260 M | -219 M | -149 M | -93.7 M | -45.5 M | -13.3 M | -1.41 M | - | - |
Total Assets |
67 M | 47.5 M | 75.3 M | 60.4 M | 69 M | 79.1 M | 79 M | 107 M | 110 M | 24.4 M | 201 K | - | - |
Cash and Cash Equivalents |
35.8 M | 32.7 M | 59.7 M | 42.9 M | 50.3 M | 74.6 M | 60.8 M | 85.4 M | 62.6 M | 22.8 M | 185 K | - | - |
Book Value |
-8.21 M | -14.4 M | 21.6 M | 10.7 M | 37.8 M | 59.1 M | 59.7 M | 88.2 M | 104 M | 21.1 M | -1.4 M | - | - |
Total Shareholders Equity |
-8.21 M | -14.4 M | 21.6 M | 10.7 M | 37.8 M | 59.1 M | 59.7 M | 88.2 M | 104 M | -11.4 M | -1.4 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Cidara Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
445 K | 510 K | 575 K | 3.31 M | 3.6 M | - | - | 344 K | 679 K | 1 M | 1.32 M | 1.62 M | - | - | - | - | 484 K | 716 K | 942 K | 942 K | 942 K | 942 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
42.4 M | 70.5 M | 75.2 M | 55.4 M | 52.6 M | 54.9 M | 50.5 M | 57.8 M | 47.5 M | 50.3 M | 53.8 M | 52.4 M | 48 M | 52.3 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 20 M | 20 M | 20 M | 20 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 6.06 M | 6.06 M | 6.06 M | 6.06 M | 3.25 M | 3.25 M | 3.25 M | 3.25 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 15 M | - | 14.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-543 M | -452 M | -441 M | -424 M | -416 M | -404 M | -407 M | -394 M | -409 M | -395 M | -377 M | -360 M | -342 M | -353 M | -335 M | -335 M | -335 M | -335 M | -260 M | -260 M | -260 M | -260 M | -219 M | -219 M | -219 M | -219 M | -149 M | -149 M | -149 M | -149 M | -93.7 M | -93.7 M | -93.7 M | -93.7 M | -45.5 M | -45.5 M | -45.5 M | -45.5 M | -13.3 M | -13.3 M | -13.3 M | -13.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
173 M | 52.7 M | 67 M | 63.5 M | 68 M | 81.7 M | 47.6 M | 66.9 M | 39.5 M | 55.3 M | 75.3 M | 51.2 M | 63.7 M | 54.2 M | 60.4 M | 60.4 M | 60.4 M | 60.4 M | 69 M | 69 M | 69 M | 69 M | 79.1 M | 79.1 M | 79.1 M | 79.1 M | 79 M | 79 M | 79 M | 79 M | 107 M | 107 M | 107 M | 107 M | 110 M | 110 M | 110 M | 110 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
164 M | 29 M | 35.8 M | 48.7 M | 50.4 M | 48 M | 32.7 M | 53.1 M | 25 M | 38 M | 59.7 M | 40.3 M | 53.1 M | 42.9 M | 42.9 M | 35.9 M | 35.9 M | 35.9 M | 50.3 M | 50.3 M | 50.3 M | 50.3 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 60.8 M | 60.8 M | 60.8 M | 60.8 M | 85.4 M | 85.4 M | 85.4 M | 85.4 M | 62.6 M | 62.6 M | 62.6 M | 62.6 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 185 K | - | - | - | 1 K | - | - | - | - | - | - | - |
Book Value |
131 M | -17.8 M | -8.21 M | 8.04 M | 15.4 M | 26.8 M | -2.9 M | 9.07 M | -7.96 M | 4.96 M | 21.6 M | -1.16 M | 15.8 M | 1.89 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 59.7 M | 59.7 M | 59.7 M | 59.7 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 104 M | 104 M | 104 M | 104 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
131 M | -17.8 M | -8.21 M | 8.04 M | 2.42 M | 15.1 M | -2.9 M | 9.07 M | -7.96 M | 4.96 M | 21.6 M | -1.16 M | 15.8 M | 1.89 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 59.7 M | 59.7 M | 59.7 M | 59.7 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 104 M | 104 M | 104 M | 104 M | -11.4 M | -11.4 M | -11.4 M | -11.4 M | -1.4 M | - | - | - | -65 K | - | - | - | - | - | - | - |
All numbers in USD currency